Melanoma Clinical Trials & Research

Melanoma Clinical Trials & Research


Memorial Sloan Kettering doctors are constantly working to improve treatment for people with melanoma through clinical trials. Participating in a clinical trial may give you access to promising melanoma treatments years before they’re available elsewhere. These studies may offer additional options if the cancer has returned after standard treatment.

Through research conducted at MSK, we’ve made enormous strides in improving the treatment options available to people worldwide. Our melanoma clinical trials have resulted in dramatic improvements in survival and quality of life for people with melanoma. Many of the effective melanoma treatments developed over the past decade were studied and tested by members of our melanoma clinical trials team. This includes the immunotherapy drugs ipilimumab (Yervoy®), nivolumab (Opdivo®), and pembrolizumab (Keytruda®), as well as the targeted therapy vemurafenib (Zelboraf®).

Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

MSK is also exploring tumor-infiltrating lymphocyte (TIL) therapy for people with melanoma. TIL therapy is a type of immunotherapy that uses a patient’s immune cells to kill cancer. When we give TIL therapy, we remove the patient’s immune cells from their tumor after surgery and give the cells a treatment that makes them multiply. We then put the cells back into the body to find and attack cancer cells.

Our doctors can help you decide if one of our clinical trials of TIL therapy is right for you:

A complete listing of clinical trials that are currently enrolling new patients is available below.

Narrow your choices
21 Clinical Trials found